• Explore /
  • Poster
  • / Real-world effectiveness and safety of camrelizumab-based neoadjuvant therapy in resectable esophageal cancer: Initial results of a prospective multicenter observational study.

Real-world effectiveness and safety of camrelizumab-based neoadjuvant therapy in resectable esophageal cancer: Initial results of a prospective multicenter observational study.

Abstract Poster

Authors

null

Yi Zhang

Zhangzhou Hospital affiliated to Fujian Medical University, Zhangzhou, China

Yi Zhang , Guoyi Shen , Rongyu Xu , Guozhong Huang , Shengsheng Yang , Qingfeng Zheng , Zhijun Huang , Hongbing Duan , Liangyun Ma , Libao Yang , Yunfeng Yi , Rongxing Liu , Kezhi Li , Shaogeng Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

DOI

10.1200/JCO.2022.40.4_suppl.250

Abstract #

250

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Yongxiang Xia

First Author: Xiaofeng Cong

First Author: Hiroyuki Asama

First Author: Di Wu